


## NCTN Pediatric Solid Tumor (other than Brain/CNS) Trials (Open as of 1/15/2026)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



## NCTN Pediatric Solid Tumor (other than Brain/CNS) Trials (Open as of 1/15/2026)

Protocol Number	Phase	Protocol Title
<b>AGCT1531</b>	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
<b>AGCT1532</b>	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors
<b>ANBL1531</b>	III	A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
<b>ANBL2131</b>	III	A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
<b>AOST2031</b>	III	A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
<b>AOST2032</b>	II/III	A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
<b>ARAR2221</b>	II	A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
<b>ARAR2331</b>	III	Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
<b>AREN1921</b>	II	Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
<b>AREN2231</b>	III	Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
<b>ARET2121</b>	II	Intravitreal Melphalan for Intraocular Retinoblastoma
<b>ARST2032</b>	III	A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma